{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=ILD&page=14",
    "query": {
      "condition": "ILD",
      "page": 14
    },
    "page_size": 10
  },
  "pagination": {
    "page": 14,
    "page_size": 10,
    "total_count": 602,
    "total_pages": 61,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=ILD&page=15&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=ILD&page=13&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-18T12:13:57.893Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02921828",
      "title": "A Safety and Efficacy of Pomalyst® Capsules Under the Actual Use in All Patients Who Are Treated With Pomalyst at a Dose of 1 mg, 2 mg, 3 mg, or 4 mg",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Multiple Myeloma"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1149,
      "start_date": "2015-04-30",
      "completion_date": "2015-12-10",
      "has_results": false,
      "last_update_posted_date": "2022-07-05",
      "last_synced_at": "2026-10-18T12:13:57.893Z",
      "location_count": 1,
      "location_summary": "No City Provided, New Jersey",
      "locations": [
        {
          "city": "No City Provided",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02921828"
    },
    {
      "nct_id": "NCT05567133",
      "title": "Risk Indicators of Sarcoidosis Evolution-Unified Protocol",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Sarcoidosis, Pulmonary"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of California, San Francisco",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "19 Years and older"
      },
      "enrollment_count": 200,
      "start_date": "2023-01-10",
      "completion_date": "2030-03-30",
      "has_results": false,
      "last_update_posted_date": "2026-01-08",
      "last_synced_at": "2026-10-18T12:13:57.893Z",
      "location_count": 2,
      "location_summary": "Baltimore, Maryland • Dallas, Texas",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05567133"
    },
    {
      "nct_id": "NCT05387239",
      "title": "Safety and Effectiveness of VL-PX10 + VL-P22 Treatment on Pulmonary Fibrosis Secondary to Covid-19",
      "overall_status": "SUSPENDED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pulmonary Fibrosis",
        "COVID-19 Respiratory Infection"
      ],
      "interventions": [
        {
          "name": "VL-PX10 and VL-P22 plus standard care",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vitti Labs, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "25 Years",
        "maximum_age": "90 Years",
        "sex": "ALL",
        "summary": "25 Years to 90 Years"
      },
      "enrollment_count": 20,
      "start_date": "2022-11-30",
      "completion_date": "2024-12",
      "has_results": false,
      "last_update_posted_date": "2024-09-19",
      "last_synced_at": "2026-10-18T12:13:57.893Z",
      "location_count": 1,
      "location_summary": "Liberty, Missouri",
      "locations": [
        {
          "city": "Liberty",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05387239"
    },
    {
      "nct_id": "NCT06581562",
      "title": "Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Rheumatoid Arthritis",
        "Pemphigus Vulgaris",
        "Granulomatosis With Polyangiitis",
        "Systemic Lupus Erythematosus"
      ],
      "interventions": [
        {
          "name": "AB-101",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "IRIS Research and Development, LLC",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2024-05-15",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2024-09-03",
      "last_synced_at": "2026-10-18T12:13:57.893Z",
      "location_count": 1,
      "location_summary": "Plantation, Florida",
      "locations": [
        {
          "city": "Plantation",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06581562"
    },
    {
      "nct_id": "NCT04093024",
      "title": "A Study to Find Out How Nintedanib is Taken up in the Body and How Well it is Tolerated in Children and Adolescents With Interstitial Lung Disease (ILD)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lung Diseases, Interstitial"
      ],
      "interventions": [
        {
          "name": "Nintedanib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Years",
        "maximum_age": "17 Years",
        "sex": "ALL",
        "summary": "6 Years to 17 Years"
      },
      "enrollment_count": 39,
      "start_date": "2019-12-03",
      "completion_date": "2022-05-24",
      "has_results": true,
      "last_update_posted_date": "2024-07-09",
      "last_synced_at": "2026-10-18T12:13:57.893Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Aurora, Colorado • Indianapolis, Indiana + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Kansas City",
          "state": "Missouri"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04093024"
    },
    {
      "nct_id": "NCT00837668",
      "title": "Stromal Gene Expression During Pulmonary Sarcoidosis",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Sarcoidosis"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Ohio State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 110,
      "start_date": "2005-04",
      "completion_date": "2012-02",
      "has_results": false,
      "last_update_posted_date": "2017-06-14",
      "last_synced_at": "2026-10-18T12:13:57.893Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00837668"
    },
    {
      "nct_id": "NCT02496585",
      "title": "Study to Evaluate the Efficacy and Safety of Nintedanib (BIBF 1120) + Prednisone Taper in Patients With Radiation Pneumonitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Cancer",
        "Lung Metastases"
      ],
      "interventions": [
        {
          "name": "Nintedanib",
          "type": "DRUG"
        },
        {
          "name": "Prednisone",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 34,
      "start_date": "2015-07-08",
      "completion_date": "2024-04-12",
      "has_results": true,
      "last_update_posted_date": "2025-04-16",
      "last_synced_at": "2026-10-18T12:13:57.893Z",
      "location_count": 12,
      "location_summary": "Boston, Massachusetts • Basking Ridge, New Jersey • Middletown, New Jersey + 9 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Basking Ridge",
          "state": "New Jersey"
        },
        {
          "city": "Middletown",
          "state": "New Jersey"
        },
        {
          "city": "Montvale",
          "state": "New Jersey"
        },
        {
          "city": "Commack",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02496585"
    },
    {
      "nct_id": "NCT07234032",
      "title": "An Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Participants With Pulmonary Hypertension Associated With Interstitial Lung Disease (PH-ILD)",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pulmonary Hypertension",
        "Interstitial Lung Disease"
      ],
      "interventions": [
        {
          "name": "Treprostinil Palmitil Inhalation Powder",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Insmed Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 344,
      "start_date": "2026-07-20",
      "completion_date": "2031-01-22",
      "has_results": false,
      "last_update_posted_date": "2026-08-13",
      "last_synced_at": "2026-10-18T12:13:57.893Z",
      "location_count": 2,
      "location_summary": "Naples, Florida • Bend, Oregon",
      "locations": [
        {
          "city": "Naples",
          "state": "Florida"
        },
        {
          "city": "Bend",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07234032"
    },
    {
      "nct_id": "NCT05321082",
      "title": "A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Progressive Fibrosing Interstitial Lung Diseases (PF-ILDs)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Lung Diseases, Interstitial"
      ],
      "interventions": [
        {
          "name": "BI 1015550",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boehringer Ingelheim",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1178,
      "start_date": "2022-11-16",
      "completion_date": "2025-04-14",
      "has_results": true,
      "last_update_posted_date": "2026-01-09",
      "last_synced_at": "2026-10-18T12:13:57.893Z",
      "location_count": 59,
      "location_summary": "Birmingham, Alabama • Tucson, Arizona • Los Angeles, California + 46 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05321082"
    },
    {
      "nct_id": "NCT00001877",
      "title": "Treatment of Pulmonary Sarcoidosis With Pentoxifylline",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Pulmonary Sarcoidosis"
      ],
      "interventions": [
        {
          "name": "Pentoxifylline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Heart, Lung, and Blood Institute (NHLBI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 100,
      "start_date": "1999-02",
      "completion_date": "2004-05",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-10-18T12:13:57.893Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00001877"
    }
  ]
}